P&G plots sale of pharma brands

Procter & Gamble wants to bail out of the pharmaceuticals business, so it has hired Goldman Sachs to find buyers for its drug brands--or figure out another way to make a graceful exit, the Financial Times reports. Known primarily for its consumer goods, P&G also has a pharma unit that brings in about $2 billion a year. Its drugs are clustered around women's health, gastrointestinal problems and musculoskeletal disorders.

The move isn't a huge surprise; P&G told analysts back in December that the company had stopped investing in drug development and would consider selling off some of its pharma brands. Back in the 1990s, when P&G started putting big bucks into pharma, returns had dwarfed those in consumer products, CEO A.G. Lafley (photo) said. That's not the case now: "Today, pharma companies trade at multiples at or below consumer products."

Plus, pharma has to contend with a harsher regulatory environment nowadays, and generics makers have grown increasingly aggressive about competing with branded meds, so the payoff from R&D isn't as certain as it once was, he said.

- read the FT story

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.